Practice Point®: Oncology

Practice Point®: Oncology

por Practice Point Communications

Episode 14 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 3

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Episode 13- Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 2

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Episode 12 - Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies - Part 1

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes. Launch Date: December 5, 2024 Release Date: December 5, 2024 Expiration Date: November 30, 2025 FACULTY Aditya Bardia, MD, MPH, FASCO Associate Professor, Medicine, Harvard Medical School Attending Physician, Medical Oncology, Massachusetts General Hospital Dana-Farber/Harvard Cancer Center, Boston, MA Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology Program The University of Chicago Medicine Chicago, IL his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Episode 11 - NF1-PN: Improving Diagnosis and Monitoring While Integrating Ongoing Updates in the Treatment Continuum

Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients. Launch Date: October 31, 2024 Release Date: October 31, 2024 Expiration Date: September 30, 2025 FACULTY Amy Armstrong, MD Assistant Professor of Pediatrics Division of Hematology/Oncology Neurofibromatosis (NF) Center Washington University School of Medicine St. Louis, Missouri This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/neurofibromatosis-type-1-related-plexiform-neurofibromas-improving-diagnosis-and-monitoring-while-integrating-ongoing-updates-in-the-treatment-continuum-1

Episode 10 - Podcasts in NSCLC Harboring EGFR Mutations: Cutting-Edge Reports from ASCO 2024

This is an accredited continuing education podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice. Launch Date: June 5, 2024 Release Date: June 5, 2024 Expiration Date: May 31, 2025 FACULTY BIO Stephen Liu, MD Associate Professor of Medicine Director of Thoracic Oncology Director of Developmental Therapeutics Lombardi Comprehensive Cancer Center Georgetown University This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/podcasts-in-nsclc-harboring-egfr-mutations-cutting-edge-reports-from-asco-2024

Episode 9 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 3: Implementing HRRm Testing in Practice

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

Episode 8 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 2: Guidelines for HRRm Testing

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

Episode 7 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Metastatic Prostate Cancer - Part 1: Rationale for HRRm Testing in Metastatic Prostate Cancer

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients. Launch Date: May 30, 2024 Release Date: May 30, 2024 Expiration Date: April 30, 2025 FACULTY BIO Andrew Armstrong, MD, ScM, FACP Professor of Medicine, Surgery, Pharmacology and Cancer Biology Duke University Tanya Dorff, MD Professor of Medicine City of Hope This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

Episode 6 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 3: Optimizing use of ADCs

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients. Launch Date: December 29, 2023 Release Date: December 29, 2023 Expiration Date: November 30, 2024 FACULTY BIOS Benjamin Levy, MD Associate Professor of Oncology Johns Hopkins Medicine Aaron Lisberg, MD Assistant Professor of Clinical Medicine University of California, Los Angeles Alexander Spira, MD, PhD, FACP Co-Director Virginia Cancer Specialists Research Institute This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode .https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

Episode 5 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 2: Impact of ADCs

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients. Launch Date: December 29, 2023 Release Date: December 29, 2023 Expiration Date: November 30, 2024 FACULTY BIOS Benjamin Levy, MD Associate Professor of Oncology Johns Hopkins Medicine Aaron Lisberg, MD Assistant Professor of Clinical Medicine University of California, Los Angeles Alexander Spira, MD, PhD, FACP Co-Director Virginia Cancer Specialists Research Institute This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode .https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

1 de 2